What is Vesugen?
A short synthetic peptide (Lys-Glu-Asp) studied for effects on the cells that line blood vessels.
Vesugen in the library · Bioregulator Peptides · Human Trials · What are peptides?
0 registered trials · 0 indexed papers · 4 human / 4 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Vesugen is described as a short synthetic peptide studied for its effects on the cells that line blood vessels. Its three amino acids are lysine, glutamic acid and aspartic acid (Lys-Glu-Asp, KED), making it a tripeptide; English abstracts of Russian-language studies sometimes spell it Vezugen.
The research includes laboratory experiments and small human reports, described as not establishing the broad circulation and anti-aging benefits often attached to the name.
More cited research
- Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes (2024, human observational)
- [The peptide correction of neurotic disorders among professional truck-drivers] (None, human trial (non-randomized))
- Peptidegic stimulation of differentiation of pineal immune cells (2011, animal)
- [Investigation of antihypoxic properties of short peptides] (2008, animal)
Related compounds
FAQ
What is Vesugen?
A short synthetic peptide (Lys-Glu-Asp) studied for effects on the cells that line blood vessels.
How many registered human trials study Vesugen?
The PeptideWhiz trial index lists 0 registered trials for Vesugen.
How much published research exists on Vesugen?
By study type, PeptideWhiz counts 4 human and 4 animal studies on Vesugen.
Which conditions is Vesugen researched for?
No condition pages are linked to this compound yet.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).